Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research note released on Tuesday. The firm issued a sell rating on the biotechnology company’s stock. Cyclacel Pharmaceuticals Price Performance Shares of NASDAQ CYCC opened at $0.60 on Tuesday. The company’s 50-day simple moving average is $0.62 and its 200-day simple […]

Related Keywords

,Cyclacel Pharmaceuticals ,Cyclacel Pharmaceuticals Price Performance ,Cyclacel Pharmaceuticals Inc ,Institutional Trading Of Cyclacel Pharmaceuticals ,Millennium Management ,News Ratings For Cyclacel Pharmaceuticals Daily ,Renaissance Technologies ,Virtu Financial ,Free Report ,Get Free Report ,Sigma Investments ,Cyclacel Pharmaceuticals Daily ,Nasdaq Cycc ,Cycc ,Medical ,Initiated Coverage ,Stocknews Com ,